WVE-007
Nucleic Acid Target: INHBE
Wave Life Sciences
Most recent annual filing: 2026-02-26
Pipeline (5 active programs)
WVE-006
Nucleic Acid Target: SERPINA1, ADAR
WVE-008
Nucleic Acid Target: PNPLA3
WVE-N531
Nucleic Acid Target: DMD exon 53
WVE-003
Nucleic Acid Target: mHTT, SNP3, HTT
Technology platforms
PRISM · GSK
Proprietary RNA medicines discovery and drug development platform combining stereochemistry-controlled oligonucleotide chemistry, multiple RNA-targeting modalities (RNAi/SpiNA, RNA editing/AIMers, antisense, splicing, bifunctional), and GalNAc or free-uptake delivery. Enables development of stereopure oligonucleotides for rare and common diseases including hepatic/metabolic, neuromuscular, and neurodegenerative diseases.
PRISM
Multi-modality RNA medicines platform combining RNAi (SpiNA stereopure siRNA) and RNA editing (AIMers) with proprietary oligonucleotide chemistry; focused on rare and common diseases including obesity, liver disease, neuromuscular, and neurological disorders
Biotech Distilled coverage (6)
- 2026-05-18 UPDATE: Wave Life Sciences (WVE) - The MZ Phenotype Is Real, And So Is the Dynamic Response
- 2026-04-30 UPDATE: Wave Life Sciences (WVE) - The Clock is Set for May 18 🔒 Paid
- 2026-04-17 UPDATE: Wave Life Sciences (WVE) - Redomiciling to Delaware 🔒 Paid
- 2026-04-05 UPDATE: Wave Life Sciences (WVE) - The Smart Money Just Faded the Retail Panic 🔒 Paid
- 2026-03-27 UPDATE: Wave Life Sciences (WVE) - The Receipts Are In on WVE-007... 🔒 Paid
- 2026-03-03 Wave Life Sciences (WVE) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.